New Hampshire will get about $144,000 as part of a nationwide, multimillion-dollar settlement against a company accused of off-label marketing for four of its drugs.

All 50 states participated in the $13.5 million settlement against Boehringer Ingelheim Pharmaceuticals, or BIPI. The states claimed BIPI misrepresented the benefits of four specialty prescription drugs approved to treat ailments ranging from metabolic syndrome to platelet conditions: Micardis, Aggrenox, Atrovent and Combivent. |Keep Reading at NHPR